Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia
Xiaoning Gao, Yong-Feng Su, Mengyue Li, Yu Jing, Jun Wang, Lei Xu, Linlin Zhang, An Wang, Yizhi Wang, Xuan Zheng, Yanfen Li, Dai‐Hong Liu
Topics & Concepts
Internal medicineMedicineRegimenDecitabineAzacitidineRefractory (planetary science)GastroenterologyAdverse effectMyeloid leukemiaHypomethylating agentClinical endpointPhases of clinical researchSingle CenterClinical trialSurgeryBiologyGeneBiochemistryGene expressionDNA methylationAstrobiologyAcute Myeloid Leukemia ResearchCAR-T cell therapy researchNeutropenia and Cancer Infections